Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03122522 · ClinicalTrials.gov registry record · Phase 2

A Study to Evaluate Adaptive Dosing of Ipilimumab and Nivolumab Combination Immunotherapy

A Phase 2 study of Metastatic Melanoma, sponsored by Memorial Sloan Kettering Cancer Center.

Active
Registry status
Phase 2
Development phase
70
Enrollment target
14
Study locations

NCT03122522 is a Phase 2 study of Metastatic Melanoma that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 70 participants, below the 83-participant average among 91 other Metastatic Melanoma trials with a reported enrollment target (16% lower). The trial reports 14 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03122522, a Phase 2 study of Metastatic Melanoma, is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
70 participants
Enrollment target
14
Study locations

Study Summary

This study will help determine whether 2 doses of the combination (ipilimumab + nivolumab) is sufficient for patients with early benefit compared to the usual way of trying to give 4 doses. If patients do not show early benefit after 2 doses, patients will be able to continue with additional ipilimumab + nivolumab, even beyond the standard 4 doses if felt in the best interest of the patient.

Conditions Studied

Metastatic Melanoma

Interventions

  • DRUG nivolumab
  • DRUG ipilimumab

Study Locations (14)

New York

  • Memorial Sloan Kettering Commack - Commack
  • Memorial Sloan Kettering Westchester - Harrison
  • Hospital for Special Surgery (Data Analysis) - New York
  • Columbia University (Data Analysis Only) - New York
  • Memorial Sloan Kettering Cancer Center - New York
  • Memorial Sloan Kettering Nassau - Uniondale

New Jersey

  • Memorial Sloan Kettering Basking Ridge - Basking Ridge
  • Memorial Sloan Kettering Monmouth - Middletown
  • Memorial Sloan Kettering Bergen - Montvale

Connecticut

  • Hartford Healthcare Alliance (Data Collection Only) - Hartford
  • Jaykumar Thumar - Hartford

Maryland

  • JOHNS HOPKINS HOSPITAL (Data Analysis Only) - Baltimore

Massachusetts

  • Brigham and Women's Hospital (Data and Specimen Analysis Only) - Boston

Pennsylvania

  • Lehigh Valley Health Network (Data Collection Only) - Allentown

Trial Details

FieldValue
Enrollment Target 70 participants
Start Date 2017-04-17
Est. Completion 2026-04
Phase Phase 2

Sponsor

Memorial Sloan Kettering Cancer Center

1,884 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03122522

The ClinicalTrials.gov registry entry for NCT03122522 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 83-participant average among 91 other Metastatic Melanoma trials with a reported enrollment target (16% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Metastatic Melanoma appearing as the primary indexed condition, and to 2 interventions - of which nivolumab is the first listed.

NCT03122522 reports 14 study locations spanning 6 distinct geographic areas - top geographies include New York, New Jersey, Connecticut.

Frequently Asked Questions

What is clinical trial NCT03122522 about?

NCT03122522 is a clinical study titled "A Study to Evaluate Adaptive Dosing of Ipilimumab and Nivolumab Combination Immunotherapy". This study will help determine whether 2 doses of the combination (ipilimumab + nivolumab) is sufficient for patients with early benefit compared to the usual way of trying to give 4 doses. If patients do not show early benefit after 2 doses, patients will be able to continue with additional ipilimu...

What is the current status of trial NCT03122522?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 70 participants. The study started on 2017-04-17. Estimated completion is 2026-04.

What conditions does trial NCT03122522 study?

This clinical trial studies the following conditions: Metastatic Melanoma.

What interventions are being tested in trial NCT03122522?

The interventions under investigation include: nivolumab (DRUG), ipilimumab (DRUG).

Who is sponsoring clinical trial NCT03122522?

This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03122522 being conducted?

This trial has 14 study locations across Connecticut, Maryland, Massachusetts, New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Metastatic Melanoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Metastatic Melanoma

All registered trials for this condition

Connecticut

All trials with a study site in Connecticut

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.